Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Integra Lifesciences Holdings Corp. (IART)
NASDAQ:IART
Holding IART?
Track your performance easily
IART Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$16.81 - $45.42
Previous Close$22.88
Volume180.75K
Average Volume (3M)961.65K
Market Cap
$1.76B
Enterprise Value$3.48B
Total Cash (Recent Filing)$277.60M
Total Debt (Recent Filing)$1.99B
Price to Earnings (P/E)―
Beta1.56
Next Earnings
Feb 19, 2025EPS Estimate
$0.85Last Dividend Ex-Date
Jul 02, 2015Dividend YieldN/A
Share Statistics
EPS (TTM)-0.09
Shares Outstanding77,163,524
10 Day Avg. Volume957,413
30 Day Avg. Volume961,655
Standard Deviation0.10
R-Squared0.34
Alpha-0.03
Financial Highlights & Ratios
Price to Book (P/B)1.16
Price to Sales (P/S)1.13
Price to Cash Flow (P/CF)19.30
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue2.24
Enterprise Value/Gross Profit3.93
Enterprise Value/Ebitda27.75
Forecast
1Y Price Target
$24.38Price Target Upside6.88% Upside
Rating ConsensusModerate Sell
Number of Analyst Covering8
Integra Lifesciences News
Bulls Say, Bears Say
Bulls Say
Leadership And ManagementA new CEO, Mojdeh Poul, with three decades of multi-divisional experience at companies like 3M, Medtronic, Boston Scientific, GE, and Teleflex, will take over in early January.
Sales PerformanceSecond-quarter sales exceeded expectations, coming in ahead of guidance and beating consensus estimates.
Strategic TransactionsThe recent Acclarent deal has exceeded initial expectations by $11 million, which should drive stronger growth ahead, particularly once operational headwinds abate.
Bears Say
Financial PerformanceManagement lowered the top end of FY24 revenue/EPS outlook due to additional 'master plan' ship holds.
Market ExpectationsThere are too many unknowns at this stage to have full confidence that IART can meet 2025 Street expectations.
Operational ChallengesSeveral of IART’s operational challenges over the last two years have proven hard to overcome.
---
Ownership Overview
3.20% Insiders
32.12% Mutual Funds
22.25% Other Institutional Investors
14.54% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Legal & RegulatoryLitigation, compliance, new legislation, and taxation risks
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
IART FAQ
What was Integra Lifesciences Holdings Corp.’s price range in the past 12 months?
Integra Lifesciences Holdings Corp. lowest stock price was $16.80 and its highest was $45.42 in the past 12 months.
What is Integra Lifesciences Holdings Corp.’s market cap?
Currently, no data Available
When is Integra Lifesciences Holdings Corp.’s upcoming earnings report date?
Integra Lifesciences Holdings Corp.’s upcoming earnings report date is Feb 19, 2025 which is in 90 days.
How were Integra Lifesciences Holdings Corp.’s earnings last quarter?
Integra Lifesciences Holdings Corp. released its earnings results on Nov 04, 2024. The company reported $0.41 earnings per share for the quarter, beating the consensus estimate of $0.39 by $0.02.
Is Integra Lifesciences Holdings Corp. overvalued?
According to Wall Street analysts Integra Lifesciences Holdings Corp.’s price is currently Undervalued.
Does Integra Lifesciences Holdings Corp. pay dividends?
Integra Lifesciences Holdings Corp. pays a Notavailable dividend of $3.18 which represents an annual dividend yield of N/A. See more information on Integra Lifesciences Holdings Corp. dividends here
What is Integra Lifesciences Holdings Corp.’s EPS estimate?
Integra Lifesciences Holdings Corp.’s EPS estimate is $0.85.
How many shares outstanding does Integra Lifesciences Holdings Corp. have?
Integra Lifesciences Holdings Corp. has 77,163,520 shares outstanding.
What happened to Integra Lifesciences Holdings Corp.’s price movement after its last earnings report?
Integra Lifesciences Holdings Corp. reported an EPS of $0.41 in its last earnings report, beating expectations of $0.39. Following the earnings report the stock price went up 25.104%.
Which hedge fund is a major shareholder of Integra Lifesciences Holdings Corp.?
Among the largest hedge funds holding Integra Lifesciences Holdings Corp.’s share is Deerfield Management Company, LP. It holds Integra Lifesciences Holdings Corp.’s shares valued at 27M.
---
Integra Lifesciences Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Sell
Average Price Target:
$24.38 (6.88% Upside)
$24.38 (6.88% Upside)
Hedge Fund Trend
Increased
By 189.0K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $25.7K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▼ 1.8%
Last 30 Days ▲ 25.3%
Last 30 Days ▲ 25.3%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-40.95%
12-Months-Change
Fundamentals
Return on Equity
-0.42%
Trailing 12-Months
Asset Growth
8.73%
Trailing 12-Months
Company Description
Integra Lifesciences Holdings Corp.
Integra LifeSciences Holdings Corp. engages in the manufacture and sale of medical instruments, devices, and equipment. It operates through the Codman Specialty Surgical, and Orthopedics and Tissue Technologies segments. The Codman Specialty Surgical segment refers to the company's neurosurgery business, which sells a full line of products for neurosurgery and neuro critical care such as tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and precision tools and instruments business, which sells instrument patterns and surgical and lighting products to hospitals, surgery centers, and dental, podiatry, and veterinary offices. The Orthopedics and Tissue Technologies segment includes offerings such as skin and wound repair, bone and joint fixation implants in the upper and lower extremities, bone grafts, and nerve and tendon repair. The company was founded by Richard E. Caruso in 1989 and is headquartered in Princeton, NJ.
---
IART Company Deck
---
IART Earnings Call
Q3 2024
0:00 / 0:00
---
IART Stock 12 Month Forecast
Average Price Target
$24.38
▲(6.88% Upside)
Technical Analysis
Best Analysts Covering IART
1 Year
1 Year Success Rate
7/9 ratings generated profit
1 Year Average Return
+18.57%
reiterated a sell rating 2 months ago
Copying Craig Bijou's trades and holding each position for 1 Year would result in 77.78% of your transactions generating a profit, with an average return of +18.57% per trade.
---